Prostate cancer progression depends in part on the complex interactions between testosterone, its active metabolite DHT, and androgen receptors. In a metastatic setting, the first line of treatment is the elimination of testosterone. However, such interventions are not curative because cancer cells evolve via multiple mechanisms to a castrate-resistant state, allowing progression to a lethal outcome. It is hypothesized that administration of antiandrogen therapy in an intermittent, as opposed to continuous, manner may bestow improved disease control with fewer treatmentrelated toxicities. The present study develops a biochemically motivated mathematical model of antiandrogen therapy that can be tested prospectively as a predictive tool. The model includes "personalized" parameters, which address the heterogeneity in the predicted course of the disease under various androgen-deprivation schedules. Model simulations are able to capture a variety of clinically observed outcomes for "average" patient data under different intermittent schedules. The model predicts that in the absence of a competitive advantage of androgen-dependent cancer cells over castration-resistant cancer cells, intermittent scheduling can lead to more rapid treatment failure as compared to continuous treatment. However, increasing a competitive advantage for hormone-sensitive cells swings the balance in favor of intermittent scheduling, delaying the acquisition of genetic or epigenetic alterations empowering androgen resistance. Given the near universal prevalence of antiandrogen treatment failure in the absence of competing mortality, such modeling has the potential of developing into a useful tool for incorporation into clinical research trials and ultimately as a prognostic tool for individual patients.
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castration resistance | continuous androgen ablation | intermittent androgen ablation | rapid antiandrogen cycling T he prostate is an accessory sex gland in the male reproductive system whose embryological development, growth, and function is dependent upon the primary male androgen, testosterone, produced primarily in the testes (1) . Similarly, the etiology and progression of epithelial cancers arising in the prostate is strongly dependent upon the presence of testosterone (2, 3) . Testosterone acts on the prostate epithelium via a highly orchestrated process integrated with multiple hormones and growth factors that continues to be elucidated (3) . Testosterone, upon entering a prostate cell, is enzymatically converted to dihydrotestosterone (DHT) by the enzyme 5α-reductase (4) . Although testosterone and DHT both bind to and activate androgen receptor (AR), DHT has 10-fold greater binding affinity and forms a more stable complex with AR than testosterone (5) . Upon binding, the androgen-AR complex is phosphorylated and dimerizes. The complex is then translocated to the cell nucleus where specific binding to the DNA elicits transcriptional activity of genes associated with proliferation, survival, and differentiation (6) .
Prostate cancer (CaP) remains a major public health problem striking nearly 200,000 American men annually and is responsible for 27,000 deaths (7) . The majority of patients diagnosed with cancer localized to the prostate are primarily treated with surgery (prostatectomy) or radiation therapy with curative intent. Yet, men with recurrence or who present with metastatic disease need additional interventions that can act systemically. In the late 1930s, Huggins et al. demonstrated that surgical castration (removal of the testes) resulted in dramatic improvement in the status of men suffering from advanced prostate cancer (8) . In subsequent decades, a number of pharmaceutical agents targeting testosterone production and signaling have been developed providing therapeutic benefits similar to surgical castration (9, 10) . These agents act by different mechanisms, including: (i) inhibition of testicular testosterone production by down-regulation of gonadotropin-releasing hormone production by the pituitary, (ii) blocking the ability of testosterone to bind the androgen receptor, (iii) inhibition of the 5α-reductase enzyme responsible for testosterone conversion to DHT (11) , and (iv) inhibition of enzymes involved in testosterone synthesis (12) .
Unfortunately, despite maintenance of castrate levels of testosterone and inhibition of AR activity, cancer cells eventually develop castration resistance after a median duration of 18-24 months of treatment, evident by the rise of prostate-specific antigen (PSA) levels, followed by progressive disease. However, the duration of response to antiandrogen therapy and the development of resistance is very heterogeneous, ranging from a few months to over 10 years (13) . The mechanistic basis for the development of castrate resistance is the result of genetic and epigenetic instability of the prostate cancer genome and the development of aberrant AR signaling pathways that allow the cancer to progress in the setting of low circulating testosterone (14, 15) . With goals of reducing the decrements in quality of life and perhaps having a therapeutic advantage of prolonging disease sensitivity to pharmacologic intervention, clinical investigators are examining a role for intermittent, as opposed to continuous, antiandrogen therapy. Intermittent treatment is accomplished by discontinuing antiandrogen therapy once a predefined clinical objective or decline in PSA has been achieved, then restarting for disease progression, or a defined PSA threshold, or after a specific time period. This process would continue in cycles until resistance develops and the disease requires other interventions.
To enhance the therapeutic efficacy of androgen-deprivation therapy, we need improved prognostic and predictive tools such as the use of mathematical models that take into account key biological features that are unique to each individual. Earlier mathematical models such as those by Jackson (16, 17) , Ideta et al. (18) , and Potter et al. (19) have considered the dynamical interplay between cancer cells and their mutations from androgensensitive to androgen-resistant phenotypes; however, these remain limited in scope and ability account for the observed heterogeneity in patients. More recently, Eikenberry et al. (20) introduced a model of early cancer development with testosterone, DHT, and AR dynamics-driven CaP cell growth. Their results suggest that low androgen levels can increase selection for castration-resistant cancer cells with elevated AR expression. We will use this evolutionary concept as the basis for the mathematical progression model proposed here.
The objective of the present paper is to develop a comprehensive mathematical model of CaP progression, focused primarily on antiandrogen therapy of advanced disease, which could be applied to different antiandrogen interventions. We consider the case of a typical patient with advanced prostate cancer. We introduce three primary cell phenotypes-healthy prostatic epithelial cells (E), androgen-dependent CaP cells (N), and castrationresistant CaP cells (M). Here, E, N, and M represent total cell number, in millions. While E cells are limited to the prostate, N and M cells are typically systemic at metastatic sites, allowing for simulation of cases where patients present with metastatic disease or relapsed/recurrent disease post radical prostatectomy or radiation. To avoid overparameterizing our system, N and M represent total CaP burden in the body and are not compartmentalized to specific metastatic sites such as bone or lymph nodes. Driving the behavior of each cell is the intracellular signaling network presented in Fig. 1 . Following Eikenberry et al. (20) , this is translated into a system of differential equations using the law of mass action, the full details of which are presented in SI Text. Our model is designed to simulate the response to antiandrogen therapy of prostate cancer up to the emergence of castration resistance, defined as the progression of the disease in the presence of castrate concentrations of serum testosterone.
Mathematical Model
We begin with a description of the equations describing the dynamics of the principle species in our model-namely, healthy epithelial and cancer cells, and intraprostatic and serum PSA concentration.
Cell Type E. Healthy epithelial cells proliferate at a rate μ E and have a natural death rate δ E that is in balance and dependent on testosterone-and DHT-activated androgen receptors (A Et and A E , respectively; Fig. 2A ). Competitive inhibition due to the presence of other cells is also incorporated in our model. The equation governing E is
Prostate volume increases with age (21) by a process known as benign prostatic hypertrophy. By choosing the carrying capacity (η E ) in the cell proliferation term to be a function of time, we can capture this variability in prostate size accurately. The parameter ϵ is a measure of the competitive interaction between healthy and cancer cells. Because N and M include CaP cells from distant metastatic sites, ϵ is assumed to have a very small or negligible value in the setting of metastatic disease but could have a role in locally advanced nonmetastatic disease.
Cell Type N. Because we are concerned with prostatic cancer that has its origins in the epithelia, the proliferation rate μ N and the death rate δ N of androgen-dependent cancer cells are significantly related to androgen-activated androgen receptors (A Nt and A N , respectively) signaling, as in the case of E. The equation for N is taken to be
Here, prolif N ¼ μ N ðA N ;A Nt ÞNð1 − ðϵE þ N þ MÞ∕η C Þ, and η C is a measure of the maximum carrying capacity of the tissue in which the cancer resides. It has been suggested that mutations leading to castration resistance are an early event, independent of androgen ablation (22) . This indicates the possibility of mutation acquisition occurring as a result of proliferation of aberrant cancer cells in N, which is accounted for by the parameter α mut , which represents the probability of a cell with androgen-dependent phenotype N mutating to a castration-resistant phenotype M. This is an important parameter in our model, because it could account for significant heterogeneity, in addition to being a key predictor of treatment outcome. Note that the overall rate of mutation (¼α mut Ã prolif N ) depends both on the number of proliferating N cells as well as how fast they proliferate.
Cell Type M. The equation governing the rate of growth of castration-resistant cancer cells is similar to that for N above,
Here, A Mt and A M are testosterone-and DHT-activated androgen receptors respectively, in M and prolif
PSA in Tissue, P. Healthy and cancerous epithelial cells of the prostate produce PSA (23) in response to activated androgen receptors (24) . However, in the noncancerous prostate the extravasation of the large PSA protein (35 kDa) into the bloodstream is hampered due to the presence of natural barriers, including the basal cell layer, prostatic basement membrane, prostatic stroma, and layers of the capillary walls (25) . The equation governing PSA production in tissue is taken to be
PSA is produced by E, N and M, in response to activated androgen receptors, at a rate prod P ¼ ∑ i¼E;N;M β P i ðA i þ A it þ ρ i Þi, where β P i is a rate constant. We also account for the possibility of an independent production mechanism, via the constant ρ i . PSA undergoes natural decay at a rate λ P and is assumed to leak into blood serum at a rate dependent on the epithelial volume relative to stromal volume of the prostate. Consequently, this leakage rate is taken to be proportional to the epithelial fraction E frac in the nonmalignant prostate-that is, the ratio of the epithelial volume to total prostatic volume.
In order to model the breakdown of natural barriers to the leakage of PSA into the blood in the presence of cancer cells, an additional leakage term is incorporated in Eq. 4. It is assumed that this additional leakage is negligible when the number of tumor cells is low, while for high numbers of tumor cells, this leakage is approximately linearly related to the number of tumor cells. This assumption is reasonable because it is to be expected that a comprehensive breakdown of the interstitial PSA barriers is more likely to occur for a higher number of tumor cells.
Serum PSA, P S . The equation governing the rate of change of serum PSA concentration is
The leakage terms in Eq. 4 correspond to source terms for serum PSA. Serum PSA is cleared from the body at a rate λ P S .
Personalized Parameters. We divide the parameters in our model into three categories: (i) parameter values from the literature, (ii) parameters derived from data fitting, and (iii) personalized parameters. The parameters in classes i and iiare derived from experimental data, humans when possible or experimental animal models as reported in ref. 26 , and in vitro data on established CaP cells lines. A detailed description of the estimation of these parameters is presented in SI Text, sections S2 and S3. Data on the development of the human prostate, together with variations in its size and serum androgen levels with age, is taken into account while extrapolating parameter values for the human case.
It is commonly recognized that prostate cancer is a highly heterogeneous disease regarding response to antiandrogen therapy and rate of progression. In addition, serum testosterone and other androgens are known to vary widely from person to person. Furthermore, although PSA within a person is a useful marker of changing tumor burden in response to therapy, PSA is a poor predictor of tumor burden between patients. The model is equipped to deal with this heterogeneity by appropriately adjusting the relevant model parameters to match each patient profile; we refer to these parameters as "personalized parameters."
Initially, cancer cells are assumed to be androgen-dependent. Following ref. 27 , the transformed cells are assumed to differ from healthy epithelial cells in having a higher net turnover rate. This is the first of our personalized parameters, because this doubling rate is estimated from patient treatment data and can vary among individuals. The simulation is allowed to run, until our virtual patient's PSA levels accumulate, at which time a screening event (screening PSA or digital rectal exam) is assumed to take place. However, in many men not undergoing screening or previously treated with local therapy that was too late, cancer cells (28) in response to intermittent androgen ablation therapy using an approach that treatment would be reinstituted arbitrarily with a PSA greater than 15 ng∕mL, and applied for a period of about 40 weeks. (C) Numerical predictions of cancer response to therapy, in terms of normalized cell number. The experimental protocol as described in B is simulated. Healthy prostatic epithelial cells (E, black curve), androgen-dependent cancer cells (N, blue curve), and castration-resistant cancer cells (M) with average phenotype (green curve) and aggressive phenotype (red curve) are plotted versus time.
have spread via the lymphatics or blood to metastatic sites. At this point antiandrogen therapy is the mainstay of treatment, and the various drugs and their actions are shown in Fig. 1 . Because this is a proof-of-concept paper, we do not distinguish between the unique aspects of each drug's action; instead we assume that the collective effect of the treatment is to reduce the bioavailability of DHT in the prostate by 60%, based upon the literature (14) . From this point onward, we may simulate continuous or intermittent therapy. As mentioned earlier, we assume that mutations leading to M phenotype emerge spontaneously as a result of N cell proliferation. The hypothesis that application of androgen ablation therapy selects for these resistant cell lines is then investigated. M cells are allowed to have a different rate of turnover in terms of proliferation and apoptosis rates as compared to N cells. The type of mutation, frequency of mutation acquisition, and mutated-cell doubling time are also designated as personalized parameters. Given that one of the common mutations observed in hormonally refractive tumors is androgen receptor overexpression, we take this example, coupled with an increased stability of the receptors, to be the mutations in M cells. Then, by changing cell doubling time and frequency of mutation acquisition, we can simulate an aggressive versus a milder M phenotype and predict responses to continuous versus intermittent therapy (on various schedules).
Results
Case Study 1: Slow Cycling of Intermittent Therapy. In 1995, Goldenberg et al. (28) published one of the first trials of intermittent androgen ablation therapy in prostate cancer patients. A group of 47 patients represented a wide range of cancer stage and grade and had an average age of 67 years. The mean follow-up time was 120 weeks and two cycles of treatment reported, lasting 73 and 75 weeks, with a mean time off therapy of 30 and 33 weeks, respectively. In seven patients with Stage D2 disease, the cancer was reported to progress to an androgen-independent stage in a mean time of 128 weeks. The treatment consisted of inhibiting pituitary gonadotropins with goserelin and androgen receptor blockade with flutamide. PSA concentrations (averaged across the entire patient dataset) were reported on an eight-week cycle from the onset of therapy. In order to fit this data to our model, we estimated the personalized parameters mentioned previously. Specifically, N and M turnover rates, probability of mutation α mut , and CaP cell-dependent PSA leakage rate parameters (γ P and K P ) are fit to the available data. It should be noted that CaP cell PSA production rate is fixed prior to performing fits at 30% of the level of healthy cells. This is essentially a free parameter in our model, and its effect on serum PSA concentration may be adjusted to required levels by correspondingly changing γ P .
Fits to the PSA data reported in ref. 28 up to the end of the first cycle of therapy indicate a doubling time of 80 d for N. This implies that the patients on average had a neoplastic transformation in their prostatic epithelia at about age 60. In order to fit the PSA data for the second cycle of therapy, from week 72 onward, it is necessary to allow for the emergence of castration resistance. In fact, an entire continuum of castration-resistant phenotypes, ranging from a milder variant (with a high doubling time of 135 d) to a more aggressive variant (with a short doubling time of 75 d) gives a good fit to the data (Fig. 2B) . Correspondingly, α mut ranges from 1 in 10,000 to 1 in 10,000,000. In all cases, γ P and K P are taken to have the same values; that is, all CaP cells are taken to have an equal effect on PSA leakage from the prostate to the serum. In the following, we treat both extremes of M phenotypes in turn.
Consider first the case when the N cells mutate to a phenotype with a slower turnover rate. If we allow the model to run on a similar schedule beyond the two cycles reported in ref. 28 (so that each time a patient's PSA levels rise above 15 ng∕mL he is put on therapy for a period of 40 weeks, while the time off therapy is at most 32 weeks, with therapy reintroduced if PSA levels rise above 15 ng∕mL before this time), the model predicts that intermittent treatment will fail within cycle 3. Treatment failure is defined by the inability of androgen ablation to reduce patient PSA levels below 4 ng∕mL. As can be seen from Fig. 2C (green curve), we have emergence of castration-resistant cancer cells leading to intermittent therapy failure; in fact even continuous therapy applied at this point is unable to eradicate the M cells, while the N cell population has been rendered insignificant. However, the cancer is kept in check as M increases at slow rate, and the physician might recommend the patient for an alternative treatment course such as surgery and/or radiotherapy. It should be noted that further mutations in the M cell population leading to uninhibited cancer growth is possible; however, this possibility is not incorporated in our current model. For more details, see SI Text, section S4.
The model can be used to simulate the case where continuous treatment had been provided to the patient instead of intermittent therapy. Numerical simulations indicate that this leads to an apparent eradication of the cancer, based upon PSA decline, within a few months. Further, a disease-free period of up to 15 years is predicted, with PSA levels remaining at very low levels during this time. At about age 85, there is evidence of emergence of castration-resistant cancer, occurring from M cells generated possibly during age 60-67, when N cells were proliferating rapidly prior to treatment. This scenario reflects a cancer that is very sensitive to therapy and with a low rate of mutational adaption to low testosterone, which occurs in some men.
Next, we consider the case when the N cells mutate to a phenotype with a higher turnover rate. The model predicts that intermittent therapy will fail within the very next cycle of treatment, due to dominance of the castration-resistant phenotype. Fig. 2C shows the temporal evolution of the various cell populations corresponding to this schedule. As can be seen, even the application of continuous therapy at this point is unable to contain the rapidly proliferating M cells (red curve). In contrast, application of continuous therapy instead of intermittent therapy from the start of treatment is predicted to result in a disease-free survival period of up to five years; for more details, see SI Text, section 4.
Case Study 2: Rapid Cycling of Intermittent Therapy. Here, we investigate the effect of competition between cells of type N and M on choice of treatment schedule. Both cell types may be competing for space and nutrients; and it is possible that in the process of mutation acquisition, cell type M becomes a poor competitor of cell type N. We quantify the competitive advantage of N over M by a parameter θ > 1,
In 2006, Feltquate et al. (29) reported on a study conducted to investigate the feasibility of rapid androgen cycling for men with progressive prostate cancer. The schedule included a 12-week induction of androgen deprivation, followed by four-week treatment cycles consisting of a gonadotropin-releasing hormone agonist analogue injection on day 1, coupled with testosterone repletion on days 1 to 7. This cycling was repeated until the cancer progressed to a castration-resistant stage. A number of PSA patterns were observed including patients whose PSA levels declined to an undetectable nadir, as well as PSA decline to a plateau, followed by eventual increase. A large subset of these patients had undergone radical prostatectomy previously and was thus being treated for metastatic disease. Although such a schedule is unlikely to be common in clinical practice we present it here to illustrate the wide scope of our model in terms of its ability to simulate a variety of treatment scenarios.
It is possible to repeat the fitting exercise described earlier for Case 1 for the various PSA patterns reported in ref. 29 . This leads to results similar to those reported above. While this serves as good validation of our model-because we are able to reproduce a number of clinically observed outcomes for a variety of different treatment strategies-we use the experimental data to test a hypothesis of possibly vital importance in determining treatment strategies for advanced CaP patients. The question we wish to ask of the model is "What if M cell type is a poor competitor of N cell type?" This is a natural question to pose; it can be an important determinant of the success of intermittent therapy in comparison to continuous treatment in terms of delaying the onset of a hormonally refractive cancer. Note that under conditions of androgen ablation, N cells have a reduced rate of proliferation and undergo apoptosis at a high rate, thereby losing their competitive edge over M cells. Fig. 3A shows a figure 2B in reference) for the case when PSA levels appear to decline to a stable plateau. Eventually the PSA levels start to rise again, at which point the patient is taken off the rapid cycling trial and put on continuous therapy. Fig. 3B shows corresponding normalized cell numbers. Note that as we are simulating a case where the patient is likely to have received a radical prostatectomy before enrollment in the study, the number of PECs has been set to zero. Prior to fitting, we make the assumption that the M phenotype has overexpression of androgen receptors coupled with an increased stability in these, as in case study 1. The personalized parameters being fit are the same as earlier.
Taking a value of θ ¼ 3, model simulations predict that the patient has an expected disease-free survival time of 28 months post rapid cycling therapy, after which PSA levels begin to rise again above a minimum threshold (taken to be 4 ng∕mL for the purposes of illustration), due to emergence of castration resistance. In contrast, had continuous therapy been provided from the start of treatment, the expected recurrence of disease would have occurred four months sooner. We now increase the parameter θ and provide rapid cycling therapy for as long as it takes for PSA levels to start rising again. This is followed by continuous therapy, as in the therapy protocol reported in ref. 29 . The time lag between disease recurrence in this case, versus providing continuous therapy from the outset, is predicted to increase exponentially (Fig. 3C) . It should be noted that for θ ≤ 2, continuous versus intermittent therapy application is favored.
Discussion
Advanced CaP is treated with drugs that either inhibit androgen synthesis or block the ability of androgens to interact with its receptor in prostate cancer cells. It has been hypothesized that intermittent as opposed to continuous therapy may have advantages for some individuals through limiting impact of treatment on quality of life and metabolic or functional health outcomes as well as prolonging the duration of response to antiandrogen therapy. Intermittent scheduling may also reduce the rate of acquisition of mutations that contribute to the castration-resistant phenotype. Yet, at the present time we lack tools to help us tailor the appropriate therapy for each individual.
The paper develops a biochemically motivated mathematical model that begins to address heterogeneity of prostate cancer progression under different antiandrogen treatment regimes. The model is formulated by a system of differential equations where most of the parameters are based on experimental data. Due to the heterogeneous nature of the disease, several "personalized parameters" are to be adjusted based upon patient data. By fitting model predictions of serum PSA levels in response to androgen ablation therapy, we provide a quantitative confirmation of the clinically held view (14) that the selective pressure of androgen blockade is a stimulus for the emergence of hormonally refractive cancers.
The model was applied to two case studies (28, 29) of intermittent therapy representing two different intermittent treatment strategies. By adjusting the few personalized parameters, we were able to fit the model simulations to the "average" patients reported in the corresponding publications for these cases. We subsequently used the model to predict the future course of the disease for the next 5-10-year period under either intermittent or continuous therapy. Which of these two strategies yields a longer remission period depends on the personalized parameters, which quantify the competitive advantage of androgen-sensitive cancer cells over mutated androgen-independent cancer cells and on the "aggresiveness" of the mutated cancer cells.
The key to a model that is predictive and prognostic is the identification and quantification of the parameters that contribute to the variation or heterogeneity that is profound in the prostate cancer population. We have postulated these to be the following parameters: rate of acquisition of new mutations conferring resistance, competitive advantage of hormone-sensitive cells over androgen-independent cells, and overall sensitivity to androgen deprivation. Having shown that model simulations agree with medical data for the average patients, the model may be used in the future to examine individual cases and clinical trials, to further quantify the contribution of these factors to treatment failure in order to predict which men would benefit from continuous therapy or one of many different strategies of intermittent therapy, thus enhancing outcome through personalized therapy. 
S2 Parameter Estimation from Literature Review and Rat Data. The estimation of parameters relating to prostatic growth as a function of androgens is discussed below. Where possible, parameter values were taken from the literature or were fit to experimental data taken from the literature using lsqcurvefit, a nonlinear least squares tool available in Matlab. Care was taken to not fit more that 2-3 parameters at one time, to a give set of data. In all other cases, biologically realistic values for parameters were chosen.
Parameter Values from Literature Review. Table S1 gives a list of parameter values obtained from a literature survey. Here, T represents testosterone, AR represents androgen receptor, and DHT represents dihydrotestosterone.
Parameter Values from Data Fitting (Rat Prostate). Estimating rate of testosterone entry into prostate and healthy cell proliferation and death as a function of testosterone-activated AR concentration in a rat model. The source of experimental data is Wright et al. (1) .
In the first set of experiments, 55-day-old male Sprague Dawley rats are castrated and treated with subcutaneously implanted testosterone pellets together with finasteride to ensure minimal or no conversion of testosterone to DHT in the prostate and killed four days after castration. Because the pellets ensure a constant amount of testosterone is released each day, we can assume serum testosterone T S is approximately constant. The model Eqs. S1-S18 may be modified as follows to simulate these experiments as follows. The unknown functions and parameters to be estimated are indicated in bold. These are the rate of testosterone entry into the prostatic epithelia f ðT S Þ, the testosterone-activated AR dependent rates of cell proliferation μ E ð0;A Et Þ and cell death δ E ð0;A Et Þ, the maximum carrying capacity of the prostate for epithelial cells E 0 , the rate of AR production α R E , and the rate of testosterone-activated AR decay λ A Et .
The experimental data to which we will fit these unknowns is indicated in rows 1-7 in Table S2 . Following Eikenberry et al. (2), we suppose that at homeostasis, free AR concentration together with activated AR concentration determines the AR production rate. Therefore, the rate of production of AR by the epithelial cells is given by the formula We first consider a prostate at homeostasis. In experiments described in (1), when a 5-mg pellet was given following castration, ventral prostatic weight was found to be at its normal (homeostatic) value of 0.449 g. The steady states of serum testosterone (T S ¼ 11.15 nM) and intraprostatic testosterone (T E ¼ 72.03 nM) corresponding to this dose will be referred to as T h S and T h E respectively. Finally, a healthy ventral prostate in a rat has been estimated to contain E h ¼ 39.42 × 10 6 cells (3). We can therefore estimate the volume V C of a typical prostatic epithelial cell to be epithelial volume E rat V divided by the number of cells. Denoting homeostatic values of free and testosteronactivated AR by R h E and A h Et respectively, Eqs. S21 and S22 give the following two equations, at the homeostatic steady state. We will use these to estimate the value of A h Et .
Fig. S1A displays total intraprostatic testosterone T þ A Et as a function of serum testosterone T S (black squares), while Fig. S2A displays total intraprostatic DHT D E þ A E as a function of T S (black squares). From these experimentally derived graphs (1), we can see that D E þ A E ≫ T þ A Et . This suggests that DHTactivated AR are more stable that testosterone-activated AR. Indeed, there is also some experimental evidence for this (4). We conclude that λ A E ≪ λ A Et , while (by Table S1 ), λ A E ≪ λ R E . It is therefore reasonable to expect that λ A Et and λ R E are close in value; here, we shall assume that they are in fact equal. Note that choosing a marginally lower value for λ A Et than λ R E does not affect the quality of our simulations, but in the absence of experimental data guiding us, we take these to be equal. Solving Eqs. S23 and S24 allows us to determine the value of A h Et ¼ 66.1019 nM, the activated AR concentration at homeostasis. Berges et al. (5) have estimated prostatic epithelial cell proliferation and death rates to be equal (with a value of 0.0083 per hour) at homeostasis. Thus we know that μ E ð0;A h Et Þð1 − E h ∕E 0 Þ ¼ 0.0083, and δ E ð0;A h Et Þ ¼ 0.0083 per hour. Further, because it takes six weeks for a rat to reach sexual maturity (6), we must have from Eq. S20 that E 0 ¼ 1.4 × E h (assuming that prostate development starts with a single cell and that it takes six weeks for the ventral prostate to reach its steady state of 39.42 million cells). In this case, μ E ð0;A h Et Þ ≈ 0.029. Next, we estimate the rate of entry of testosterone form the serum into the prostate f ðT S Þ by observing that because the binding of testosterone to its receptors occurs at a very fast time scale in comparison to the rates of proliferation or apoptosis of cells and that from ref. 1 we have estimates of intraprostatic testosterone at day 4, versus serum testosterone levels (in columns 1 and 4 of Table S2 ), we may solve Eqs. S19, S21, and S22 to their steady state for each given value of T S and T in order to estimate a value for f ðT S Þ. Taking a Hill function-like form for f ðT S Þ as given by Eq. S9 provides the best fit. We assume here that the prostate produces testosterone locally at a very low rate. This is corroborated by data from ref. 1, where small amount of testosterone were detected in the prostates of castrated rats that were given no testosterone (see figure 2 in the referenced paper). The fitted parameter values are reported in Table S3 .
We finally solve the entire system of Eqs. S19-S22 to estimate the precise functional forms of μ E ð0;A Et Þ and δ E ð0;A Et Þ by fitting to cell count data as shown in column 5, rows 1-7 of Table S2 . The resulting fits are shown in Fig. S1C . The estimated functional form for epithelial cell proliferation is given below.
This functional form is chosen because it is known that activated AR dimerize before translocating to the nucleus and inducing downstream effects (7); indeed the enzymatic process A Et þ A Et ⇌ B where B translocates to the nucleus leads to Hill's dynamics with exponent 2. From the homeostasis data we can reduce the number of unknowns in this expression by 1 parameter. Note that we get our fit by taking δ E ð0;A Et Þ to be constant, at 0.0083 per hour. In other words, the model predicts the best fit if we assume that testosterone primarily induces a proliferative effect, rather than a prosurvival effect in prostatic epithelial cells.
The fitted values are shown in Table S3 . The proliferation and death rates are plotted versus various values of A Et in Fig. S1B .
Estimating rate of testosterone conversion to DHT and cell proliferation and death as a function of DHT-activated AR concentration in a rat model. In another set of experiments described in Wright et al.
(1), the castrated rats as described previously are not treated with finasteride, allowing for the conversion of testosterone to DHT in the prostate. The model Eqs. S1-S18 can be modified to simulate these experiments as in the equations that follow. The unknown functions and parameters to be estimated are indicated in bold. These include parameters relating to the rate of conversion of testosterone to DHT mediated by the enzyme 5-α reductase β T and K T , and the DHT-activated AR dependent rates of cell proliferation μ E ðA E ;A Et Þ and cell death δ E ðA E ;A Et Þ.
The experimental data to which we will fit these unknowns is indicated in rows 8-13 of Table S2 . We have two reservations about this data. First, note that the twelfth row seems to be in disagreement with all the other rows because it implies that lower serum testosterone results in higher intraprostatic DHT as compared with homeostatic values (row 11) and that these higher DHT values result in a lower prostatic weight. The second reservation is concerned with the testosterone level T S ¼ 3.767 nM in row 13. This level is much too high because it implies that a 4.6-fold increase in serum testosterone leads to only a 1.3-fold increase in DHT levels. In view of these reservations, while performing parameter estimation we shall disregard the data in row 12 and the value of T S in row 13 (but retain the value of D E þ A E ¼ 42.85 corresponding to a prostatic weight of 0.541 g).
As in the previous section, following Eikenberry et al. (3) , the rate of production of AR by the epithelial cells can be calculated to be
We first estimate the rate of conversion of testosterone into DHT in the prostatic epithelium by observing that because the chemical reactions occur at a very fast time scale in comparison to the rates of proliferation or apoptosis of cells and that from ref. 1 we have estimates of intraprostatic DHT at day 4, versus serum testosterone levels (in columns 1 and 4, rows 8-13 of Table S2 ), we may solve the above system of equations, barring the cell equation, to its steady state for each given value of T S and D E in order to estimate a value for β T and K T , that fits this data best. The corresponding fits are shown in Fig. S2A . The values of the parameters are shown in Table S3 We finally solve the entire system of equations S26-S31 to estimate the precise functional forms of μ E ðA E ;A Et Þ and δ E ðA E ;A Et Þ, by fitting to cell count data as shown in column 5, rows 8-13 of Table S2 . The resulting fits are shown in Fig. S2C . The estimated functional forms for epithelial cell proliferation (the choice of this form is explained earlier) and death rates are given by Eqs. S5 and S6, respectively. Note that the death rate is assumed to decrease as the concentration of DHT-activated AR increases. This is in concordance with experimental evidence, which indicates that activated AR lead to prosurvival signaling in addition to providing proliferative cues to the epithelial cells (8, 9) . From the homeostasis data we can reduce the number of unknowns in these expressions by 1 parameter each. The fitted values are shown in Table S3 . The proliferation and death rates are plotted versus various values of A E in Fig. S2B . Having extensively estimated parameters for the development of a rat prostate, including intracellular biochemical reaction dynamics, we now turn our attention to a human prostate. The weight of the typical prepubertal prostate is 2 g, while the mature gland weighs 20 g. Further, the doubling time of the prostate has been calculated to be 2.76 years (10) . We therefore need to adjust the cell turnover rates as estimated earlier to fit this data. In the absence of evidence to the contrary, we assume that the prostatic epithelial volume to prostate volume ratio is preserved between rats and humans. Then, a fully developed and healthy human prostate must contain approximately 1.86 billion epithelial cells. We further assume that all kinetic parameters and dependence of cell proliferation and death rates on androgens are also preserved between rats and humans. In this case, the only parameters that need to be altered are q E 1 and q Et 1 , the maximal proliferation rates, and q E 3 , the maximal death rate of epithelial cells and the constants q E 2 , q Et 2 and q E 4 . (see Eqs. S5 and S6). Additionally, in order to account for the fact that at least 90% of the androgen in a human prostate is in the form of DHT, the value of AR expression per cell r 0 E is adjusted to 180 nM and maximal rate of testosterone conversion to DHT β T is increased fourfold. The values of the scaled variables are given in Table S4 .
The natural enlargement of the prostate that occurs over time is accounted for by estimating a functional form for prostate volume P vol as given by Eq. S18. The data being fit is in the form of average prostate volumes versus age, taken from ref. 11. The resultant fit is shown in Fig. S3A and variable values given in Table S4 . Finally, testosterone production in men also falls with age, and this is taken into account by making serum testosterone T S a function of time as given by Eq. S1. Note that we are not concerned here with the precise mechanism of testosterone production; hence a phenomenological choice has been made to describe the temporal evolution for this quantity, rather than a detailed biochemical formulation as was done for intraprostatic hormones and proteins. The data being fit is in the form of average serum testosterone values versus age, taken from Oddens and Vermeulen (12) . The resultant fit is shown in Fig. S3B and variable values given in Table S4 .
Estimating PSA production and leakage rates. The equations describing PSA production in the prostate, and its leakage into blood serum has been discussed in Results in the main text. In the absence of cancer, average serum PSA values are observed to increase with age. We account for this heterogeneity by making the rate of PSA leakage dependent on the endothelial fraction of the prostate, as in Eqs. S15 and S16. The data being fit are taken from Richardson and Oesterling (13) , with the resultant fit shown in Fig. S3C . In order to obtain this fit, it is necessary to assume that the epithelial fraction in the human prostate increases with age; consequently, the maximal carrying capacity of the prostate for epithelial cells η E is made a function of age. The unknowns β P E and ρ E in Eq. S15 relating to intracellular PSA production are assigned arbitrary values, because there is no data available to fit these to. The fitted functional form is given below, and parameters in Table S4 .
S4 Personalized Parameters (Prostate Cancer Progression and Treatment). Fits of parameters relating to N and M cell turnover rates, probability of mutation from N to M phenotype α mut , and CaP cell-dependent PSA leakage rate parameters (γ P and K P ) are fit to the available data. As mentioned in the main text, cancer cell PSA production rate β P N is kept fixed throughout the simulations at 30% of the value of β P E . The mutated cells (M) are presumed to have a fourfold receptor overexpression level and fourfold increase in stability of receptors (see Table S1 ). All other constants relating to intracellular processes in both N and M cell are kept at the same values as for the E cell type. The various parameter values are reported in Table S5 (Case study 1, muta-tion to average phenotype-rows 1-14 (rows 1-4 are fixed prior to fitting), and Case study 1, mutation to aggressive phenotyperows 15-18), and Table S6 (Case study 2). Note that for Case study 2, the parameter θ is a measure of the competitive advantage of N-cells over M-cells.
Sensitivity Analysis on the Probability of Mutation Acquisition. Given the importance of the parameter α mut that measures the probability of mutation acquisition by N cells, we conduct a sensitivity analysis on its effect on treatment outcome, in Case Study 2 (see main text). Increasing its value by 100% is predicted to result in rapid androgen cycling treatment failure at 20 months as compared to 26 months in the control simulation case. If the patient is put on continuous treatment at this point, the expected disease free survival time is 25 months as compared to 29 months in the control. Interestingly, increasing α mut appears to offset the competitive disadvantage of M cells versus N cells to a certain extent; had continuous therapy been provided from the start of treatment, the expected recurrence of disease would have occurred only two months sooner as compared to rapid cycling therapy. In contrast, decreasing α mut by 50% is predicted to increase the time of rapid cycling therapy efficacy by five months as compared to the control case. If the patient is put on continuous treatment at this point, the expected disease free survival time is three months longer. As in the control case, had continuous therapy been provided from the start of treatment, the expected recurrence of disease would have occurred five months sooner than in the rapid cycling case. 
